TOTUM•63, prediabetes
Acquiring of the patent in China;
Logical distributions approving the R&D work performed;
Declaration of the execution of a clinical method of activity concentrate by INAF at Laval University in Quebec City, in organization with Nestlé Health Science.
TOTUM•070, decrease of LDL-hypercholesterolemia (“awful cholesterol”)
Dispatch of the HEART Phase II clinical review;
Finish of enrollment affirmed in September.
TOTUM•854, decrease of circulatory strain
Speed increase of the improvement program following the introduction of preclinical information at the yearly congress of the European Society of Hypertension and the International Society of Hypertension;
Dispatch of three clinical investigations that could prompt commercialization as long as 3 years in front of the underlying arrangement.
Reinforcing the association
Getting of ISO-9001:2015 confirmation for all the Company’s exercises;
Arrangement of Sébastien BESSY as Chief Operating Marketing and Business Officer.
A drawn out secure monetary circumstance
Income of €25.8 million as of June 30, 2021;
Monetary perceivability until the principal half of 2024, barring likely extra incomes.
Valbiotis (FR0013254851 – ALVAL, PEA/SME qualified) (Paris:ALVAL), a French innovative work organization focused on logical advancement for forestalling and fighting metabolic sicknesses, distributes its monetary report for the main portion of 2021 and gives a report on the Company’s advancement
SUBSCRIBE TO OUR NEWSLETTER
First NameLast NameEmail AddressContact NumberJob TitleCompany NameCountry Name Select AfghanistanAlbaniaAlgeriaAndorraAngolaAntigua and BarbudaArgentinaArmeniaAustraliaAustriaAustrian EmpireAzerbaijanBaden*Bahamas, TheBahrainBangladeshBarbadosBavaria*BelarusBelgiumBelizeBenin (Dahomey)BoliviaBosnia and HerzegovinaBotswanaBrazilBruneiBrunswick and LüneburgBulgariaBurkina Faso (Upper Volta)BurmaBurundiCabo VerdeCambodiaCameroonCanadaCayman Islands, TheCentral African RepublicCentral American Federation*ChadChileChinaColombiaComorosCongo Free State, TheCosta RicaCote d’Ivoire (Ivory Coast)CroatiaCubaCyprusCzechiaCzechoslovakiaDemocratic Republic of the CongoDenmarkDjiboutiDominicaDominican RepublicDuchy of Parma, The*East Germany (German Democratic Republic)*EcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFederal Government of Germany (1848-49)*FijiFinlandFranceGabonGambia, TheGeorgiaGermanyGhanaGrand Duchy of Tuscany, The*GreeceGrenadaGuatemalaGuineaGuinea-BissauGuyanaHaitiHanover*Hanseatic Republics*Hawaii*Hesse*Holy SeeHondurasHungaryIcelandIndiaIndonesiaIranIraqIrelandIsraelItalyJamaicaJapanJordanKazakhstanKenyaKingdom of Serbia/Yugoslavia*KiribatiKoreaKosovoKuwaitKyrgyzstanLaosLatviaLebanonLesothoLew Chew (Loochoo)*LiberiaLibyaLiechtensteinLithuaniaLuxembourgMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMauritaniaMauritiusMecklenburg-Schwerin*Mecklenburg-Strelitz*MexicoMicronesiaMoldovaMonacoMongoliaMontenegroMoroccoMozambiqueNamibiaNassau*NauruNepalNetherlands, TheNew ZealandNicaraguaNigerNigeriaNorth German Confederation*North German Union*North MacedoniaNorwayOldenburg*OmanOrange Free State*PakistanPalauPanamaPapal States*Papua New GuineaParaguayPeruPhilippinesPiedmont-Sardinia*PolandPortugalQatarRepublic of Genoa*Republic of Korea (South Korea)Republic of the CongoRomaniaRussiaRwandaSaint Kitts and NevisSaint LuciaSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSchaumburg-Lippe*SenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon Islands, TheSomaliaSouth AfricaSouth SudanSpainSri LankaSudanSurinameSwedenSwitzerlandSyriaTajikistanTanzaniaTexas*ThailandTimor-LesteTogoTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTuvaluTwo Sicilies*UgandaUkraineUnion of Soviet Socialist Republics*United Arab Emirates, TheUnited Kingdom, TheUruguayUzbekistanVanuatuVenezuelaVietnamWürttemberg*YemenZambiaZimbabwe
I would like to receive information from suppliers sponsoring this content and willing to share the information above with business book 25.SEND
Sébastien PELTIER, Chairman of the Board of Directors at Valbiotis, remarks: “2020 was a urgent year for Valbiotis with the finish of our vital worldwide association with Nestlé Health Science for TOTUM•63, our lead item committed to the decrease of hazard factors for type 2 diabetes. This organization has conclusively fortified our perceivability on a worldwide scale. It has opened up promising showcasing possibilities for us as we enter the last period of improvement of this dynamic substance, which has as of now been logically demonstrated to be compelling. Furthermore, most importantly, it has reinforced our purpose to seek after our vital guide. This is the thing that 2021 is tied in with: trying harder to arrive at new achievements with TOTUM•63, just as with different items in our portfolio. In the primary portion of the year, we were on track. As well as accomplishing new logical achievements and fortifying our association, we likewise got our monetary assets on a drawn out premise. These accomplishments empower us to move toward our next challenges with certainty, upheld by the responsibility of our representatives and the essential help of our investors.”
Principle accomplishments since the start of 2021: beginning of the year completely in accordance with the guide
TOTUM•63, prediabetes
Acquiring of Chinese patent
In the space of protected innovation, further advancement was made in the principal half of the year, with the allowing of a patent in China for TOTUM•63. Reported in May 2021 (public statement of May 19, 2021), this patent awards wide assurance for the creation and utilization of this substance. It additionally presents a restraining infrastructure on double-dealing in this essential country, one of the most influenced by metabolic sicknesses, where the pervasiveness of prediabetes in the grown-up populace is assessed at 35%1, for example 390 million individuals, and that of overweight and heftiness at 50%2. This is a substantial illustration of the Society’s worldwide assurance procedure, with licenses having now been gained in almost 50 nations, including across Europe, the United States and China.
In accordance with the methodology created with Nestlé Health Science, information on TOTUM•63 has been distributed in three worldwide friend checked on diaries, featuring the emphasis on logical advancement, which is conclusive in getting ready for future commercialization. These articles (official statement of June 3, 2021) were distributed in the American Journal of Physiology-Endocrinology and Metabolism, the International Journal of Obesity and Nutrients. They comprise an approval by established researchers of the work performed and permit the last to all the more likely comprehend the instrument of activity of this dynamic substance.
Declaration of the execution of a clinical method of activity concentrate by INAF at Laval University in Quebec City (public statement of June 28, 2021)
On the logical front, another review co-planned by Valbiotis groups, INAF specialists and Nestlé Health Science specialists was likewise declared. It ought to give extra information to help logical correspondence and the advertising of this dynamic substance. The dispatch of the review is gotten ready for the final quarter of 2021.
TOTUM•070, decrease of LDL-hypercholesterolemia (“terrible cholesterol”)
)
Dispatch of the HEART Phase II clinical review and First Patient First Visit
In February 2021 (public statement of February 15, 2021), the organization was approved to dispatch the HEART Phase II clinical review and accordingly finished the First Patient First Visit (public statement of February 22, 2021). The enrollment of the last volunteer in this review was reported toward the start of September 2021 (public statement of September 6, 2021), completely in accordance with the review’s guide. Results are normal in the second quarter of 2022.
This review will assess the impact of TOTUM•070 on the decrease of LDL-cholesterol, a danger factor for cardiovascular illness, in individuals with gentle to direct hypercholesterolemia.
With the synchronous dispatch of a clinical report to portray every one of the metabolites and recognize their belongings in human cell models, just as broad preclinical work to be submitted to the American Heart Association (AHA) yearly gathering in November 2021, this program will give thorough information to situate TOTUM•070 as an advancement development in the cardiovascular danger anticipation market
TOTUM•854, decrease of circulatory strain
- Speed increase of the improvement program following the introduction of preclinical information at the yearly congress of the European Society of Hypertension and the International Society of Hypertension;
- Dispatch of three clinical examinations that could prompt commercialization as long as 3 years in front of the underlying arrangement.
- Fortifying the association
Acquiring of ISO-9001:2015 accreditation for all the Company’s exercises;
- Arrangement of Sébastien BESSY as Chief Operating Marketing and Business Officer.
- A drawn out secure monetary circumstance
- Income of €25.8 million as of June 30, 2021;
- Monetary perceivability until the principal half of 2024, barring likely extra incomes.
- September 30, 2021 01:35 AM Eastern Daylight Time
- LA ROCHELLE, France- – (BUSINESS WIRE)- –
Valbiotis (FR0013254851 – ALVAL, PEA/SME qualified) (Paris:ALVAL),
a French innovative work organization focused on logical development for forestalling and battling metabolic illnesses, distributes its monetary report for the principal half of 2021 and gives a report on the Company’s advancement.
Sébastien PELTIER, Chairman of the Board of Directors at Valbiotis, remarks: “2020 was a crucial year for Valbiotis with the finish of our key worldwide organization with Nestlé Health Science for TOTUM•63, our lead item committed to the decrease of hazard factors for type 2 diabetes. This association has unequivocally reinforced our perceivability on a worldwide scale. It has opened up promising showcasing possibilities for us as we enter the last period of advancement of this dynamic substance, which has as of now been logically shown to be powerful. What’s more, most importantly, it has fortified our purpose to seek after our key guide. This is the thing that 2021 is tied in with: trying harder to arrive at new achievements with TOTUM•63, just as with different items in our portfolio. In the principal half of the year, we were on track. As well as accomplishing new logical achievements and reinforcing our association, we additionally got our monetary assets on a drawn out premise. These accomplishments empower us to move toward our next challenges with certainty, sponsored by the responsibility of our workers and the urgent help of our investors.”
Primary accomplishments since the start of 2021: beginning of the year totally in accordance with the guide
TOTUM•63, prediabetes
Getting of Chinese patent
In the space of licensed innovation, further advancement was made in the main portion of the year, with the conceding of a patent in China for TOTUM•63. Reported in May 2021 (public statement of May 19, 2021), this patent awards expansive insurance for the arrangement and utilization of this substance. It likewise gives a syndication on abuse in this essential country, one of the most influenced by metabolic illnesses, where the predominance of prediabetes in the grown-up populace is assessed at 35%1, for example 390 million individuals, and that of overweight and weight at 50%2. This is a substantial illustration of the Society’s worldwide assurance methodology, with licenses having now been procured in almost 50 nations, including across Europe, the United States and China.
First distributions of logical articles in three worldwide diaries
In accordance with the procedure created with Nestlé Health Science, information on TOTUM•63 has been distributed in three global friend surveyed diaries, featuring the attention on logical advancement, which is unequivocal in getting ready for future commercialization. These articles (official statement of June 3, 2021) were distributed in the American Journal of Physiology-Endocrinology and Metabolism, the International Journal of Obesity and Nutrients. They establish an approval by mainstream researchers of the work performed and permit the last to all the more likely comprehend the instrument of activity of this dynamic substance.
